European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myeloma
European Commission (EC) has approved elotuzumab –marketed under the brand Empliciti by Bristol-Myers Squibb (BMS)– plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who…